Delirium prevention and prediction,Part 2
Not Applicable
- Conditions
- delirium
- Registration Number
- JPRN-UMIN000015681
- Lead Sponsor
- Juntendo University
- Brief Summary
We found that development of delirium occurred significantly less often among patients taking suvorexant than those taking placebo (0% [n/N=0/36] vs.17% [6/36], P=.025). Comparison by log-rank test also showed that development of delirium occurred significantly less often among patients taking suvorexant than those taking placebo (chi-square=6.46, P=.011). Analysis of variance revealed a tendency for main effect of treatment (F=3.79, P=.053) on Sleep-wake cycle disturbance score (item 1) of DRS-R98-J.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have an expected stay or life expectancy less than 2 night
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method